.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Julphar
UBS
Daiichi Sankyo
Teva
Federal Trade Commission
Merck
Chinese Patent Office
Queensland Health
Harvard Business School

Generated: September 22, 2017

DrugPatentWatch Database Preview

DESFERAL Drug Profile

« Back to Dashboard

Which patents cover Desferal, and when can generic versions of Desferal launch?

Desferal is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in DESFERAL is deferoxamine mesylate. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the deferoxamine mesylate profile page.

Summary for Tradename: DESFERAL

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list67
Clinical Trials: see list11
Patent Applications: see list3,584
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DESFERAL at DailyMed

Pharmacology for Tradename: DESFERAL

Drug ClassIron Chelator
Mechanism of ActionIron Chelating Activity
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
DESFERAL
deferoxamine mesylate
INJECTABLE;INJECTION016267-002May 25, 2000APRXYesYes► Subscribe► Subscribe► Subscribe
Novartis
DESFERAL
deferoxamine mesylate
INJECTABLE;INJECTION016267-001Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: DESFERAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
DESFERAL
deferoxamine mesylate
INJECTABLE;INJECTION016267-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
AstraZeneca
Deloitte
Moodys
Chinese Patent Office
McKesson
Federal Trade Commission
Daiichi Sankyo
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot